Professor Paola Piccini

Publications


Journals

  • Politis M; Wu K; Loane C; Quinn NP; Brooks DJ; Oertel WH; Björklund A; Lindvall O; et alPiccini P. (4 Apr 2012). Serotonin neuron loss and nonmotor symptoms continue in Parkinson's patients treated with dopamine grafts. Sci Transl Med. 4:128ra41. DOI.
  • Politis M; Piccini P. (2 Feb 2012). Positron emission tomography imaging in neurological disorders. J Neurol. DOI.
  • Politis M; Loane C; Wu K; Brooks DJ; Piccini P. (Sep 2011). Serotonergic mediated body mass index changes in Parkinson's disease. Neurobiol Dis. 43:609-615. DOI.
  • Politis M; Loane C; Wu K; Brooks DJ; Piccini P. (1 Sep 2011). Serotonergic mediated body mass index changes in Parkinson's disease. NEUROBIOLOGY OF DISEASE. 43:609-615. DOI.
  • Politis M; Oertel WH; Wu K; Quinn NP; Pogarell O; Brooks DJ; Bjorklund A; Lindvall O; et alPiccini P. (Sep 2011). Graft-induced dyskinesias in Parkinson's disease: High striatal serotonin/dopamine transporter ratio. Mov Disord. 26:1997-2003. DOI.
  • O'Sullivan SS; Loane CM; Lawrence AD; Evans AH; Piccini P; Lees AJ. (1 Jun 2011). Sleep disturbance and impulsive-compulsive behaviours in Parkinson's disease. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 82:620-622. DOI.
  • Meissner WG; Frasier M; Gasser T; Goetz CG; Lozano A; Piccini P; Obeso JA; Rascol O; et alSchapira A; Voon V; Weiner DM; Tison F; Bezard E. (1 May 2011). Priorities in Parkinson's disease research. NATURE REVIEWS DRUG DISCOVERY. 10:377-393. Author weblink DOI.
  • O'Sullivan SS; Wu K; Politis M; Lawrence AD; Evans AH; Bose SK; Djamshidian A; Lees AJ; et alPiccini P. (1 Apr 2011). Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours. BRAIN. 134:969-978. Author weblink DOI.
  • Owen DR; Piccini P; Matthews PM. (Mar 2011). Towards molecular imaging of multiple sclerosis. Mult Scler. 17:262-272. DOI.
  • Politis M; Pavese N; Tai YF; Kiferle L; Mason SL; Brooks DJ; Tabrizi SJ; Barker RA; et alPiccini P. (Feb 2011). Microglial activation in regions related to cognitive function predicts disease onset in Huntington's disease: a multimodal imaging study. Hum Brain Mapp. 32:258-270. DOI.
  • Tai YF; Hoshi R; Brignell CM; Cohen L; Brooks DJ; Curran HV; Piccini P. (Mar 2011). Persistent nigrostriatal dopaminergic abnormalities in ex-users of MDMA ('Ecstasy'): an 18F-dopa PET study. Neuropsychopharmacology. 36:735-743. DOI.
  • Politis M; Wu K; Loane C; Turkheimer FE; Molloy S; Brooks DJ; Piccini P. (23 Nov 2010). Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology. 75:1920-1927. DOI.
  • Wu K; Politis M; Warsi S; Loane C; O'Sullivan S; Lees A; Piccini P. (15 Sep 2010). Measuring Severity of Impulse Control Disorders in Parkinson's Disease Using Objective Validated Questionnaire. MOVEMENT DISORDERS. 25:S683-S684. Author weblink.
  • Wu K; Politis M; O'Sullivan S; Bose S; Lees A; Piccini P. (15 Sep 2010). Impulse Control Disorders Subtypes in Parkinson's Disease: Clinical and PET Correlations. MOVEMENT DISORDERS. 25:S725-S726. Author weblink.
  • Politis M; Piccini P. (2010). Brain imaging after neural transplantation. Prog Brain Res. 184:193-203. DOI.
  • Kiferle L; Politis M; Muraro PA; Piccini P. (Feb 2011). Positron emission tomography imaging in multiple sclerosis-current status and future applications. Eur J Neurol. 18:226-231. DOI.
  • Politis M; Wu K; Molloy S; G Bain P; Chaudhuri KR; Piccini P. (15 Aug 2010). Parkinson's disease symptoms: the patient's perspective. Mov Disord. 25:1646-1651. DOI.
  • Politis M; Wu K; Loane C; Kiferle L; Molloy S; Brooks DJ; Piccini P. (Oct 2010). Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. Neurobiol Dis. 40:216-221. DOI.
  • Politis M; Wu K; Loane C; Quinn NP; Brooks DJ; Rehncrona S; Bjorklund A; Lindvall O; et alPiccini P. (30 Jun 2010). Serotonergic neurons mediate dyskinesia side effects in Parkinson's patients with neural transplants. Sci Transl Med. 2:38ra46. DOI.
  • Pavese N; Kiferle L; Piccini P. (Dec 2009). Neuroprotection and imaging studies in Parkinson's disease. Parkinsonism Relat Disord. 15 Suppl 4:S33-S37. DOI.
  • Pavese N; Moore RY; Scherfler C; Khan NL; Hotton G; Quinn NP; Bhatia KP; Wood NW; et alBrooks DJ; Lees AJ; Piccini P. (Mar 2010). In vivo assessment of brain monoamine systems in parkin gene carriers: a PET study. Exp Neurol. 222:120-124. DOI.
  • Pavese N; Khan NL; Scherfler C; Cohen L; Brooks DJ; Wood NW; Bhatia KP; Quinn NP; et alLees AJ; Piccini P. (15 Nov 2009). Nigrostriatal Dysfunction in Homozygous and Heterozygous Parkin Gene Carriers: An F-18-Dopa PET Progression Study. MOVEMENT DISORDERS. 24:2260-2266. Author weblink DOI.
  • Wu K; Politis M; Piccini P. (Nov 2009). Parkinson disease and impulse control disorders: a review of clinical features, pathophysiology and management. Postgrad Med J. 85:590-596. DOI.
  • Pavese N; Politis M; Tai YF; Barker RA; Tabrizi SJ; Mason SL; Brooks DJ; Piccini P. (Feb 2010). Cortical dopamine dysfunction in symptomatic and premanifest Huntington's disease gene carriers. Neurobiol Dis. 37:356-361. DOI.
  • Politis M; Pavese N; Tai YF; Tabrizi SJ; Barker RA; Piccini P. (1 Nov 2008). Hypothalamic involvement in Huntingtons disease: an in vivo PET study. BRAIN. 131:2860-2869. Author weblink DOI.
  • Politis M; Piccini P; Pavese N; Koh SB; Brooks DJ. (Nov 2008). Evidence of dopamine dysfunction in the hypothalamus of patients with Parkinson's disease: an in vivo 11C-raclopride PET study. Exp Neurol. 214:112-116. DOI.
  • Reuter I; Tai YF; Pavese N; Chaudhuri KR; Mason S; Polkey CE; Clough C; Brooks DJ; et alBarker RA; Piccini P. (1 Aug 2008). Long-term clinical and positron emission tomography outcome of fetal striatal transplantation in Huntington's disease. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 79:948-951. Author weblink DOI.
  • Piccini P. (1 Sep 2004). The contribution of neuroirnaging to the preclinical diagnosis of Parkinson's disease. EUROPEAN JOURNAL OF NEUROLOGY. 11:337-337. Author weblink.
  • Sawamoto N; Piccini P; Hotton G; Pavese N; Thielemans K; Brooks DJ. (1 May 2008). Cognitive deficits and striato-frontal dopamine release in Parkinson's disease. BRAIN. 131:1294-1302. Author weblink DOI.
  • Turkheimer FE; Boussion N; Anderson AN; Pavese N; Piccini P; Visvikis D. (1 Apr 2008). PET image denoising using a synergistic multiresolution analysis of structural (MRI/CT) and functional datasets. JOURNAL OF NUCLEAR MEDICINE. 49:657-666. Author weblink DOI.
  • Hoshi R; Cohen L; Lemanski L; Piccini P; Bond A; Curran HV. (1 Aug 2007). Ecstasy (MDMA) does not have long-term effects on aggressive interpretative bias: A study comparing current and ex-ecstasy users with polydrug and drug-naive controls. EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY. 15:351-358. Author weblink DOI.
  • Hoshi R; Mullins K; Boundy C; Brignell C; Piccini P; Curran HV. (1 Oct 2007). Neurocognitive function in current and ex-users of ecstasy in comparison to both matched polydrug-using controls and drug-naive controls. PSYCHOPHARMACOLOGY. 194:371-379. Author weblink DOI.
  • Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P. (1 Jul 2007). Microglial activation in presymptomatic Huntington's disease gene carriers. BRAIN. 130:1759-1766. Author weblink DOI.
  • Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P. (30 Apr 2007). Imaging microglial activation in Huntington's disease. Brain Res Bull. 72:148-151. DOI.
  • Pavese N; Evans AH; Tai YF; Hotton G; Brooks DJ; Lees AJ; Piccini P. (14 Nov 2006). Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology. 67:1612-1617. DOI.
  • Tai YF; Ahsan RL; de Yébenes JG; Pavese N; Brooks DJ; Piccini P. (Mar 2007). Characterization of dopaminergic dysfunction in familial progressive supranuclear palsy: an 18F-dopa PET study. J Neural Transm. 114:337-340. DOI.
  • Piccini P; Brooks DJ. (Dec 2006). New developments of brain imaging for Parkinson's disease and related disorders. Mov Disord. 21:2035-2041. DOI.
  • Pavese N; Gerhard A; Tai YF; Ho AK; Turkheimer F; Barker RA; Brooks DJ; Piccini P. (13 Jun 2006). Microglial activation correlates with severity in Huntington disease: a clinical and PET study. Neurology. 66:1638-1643. DOI.
  • Evans AH; Pavese N; Lawrence AD; Tai YF; Appel S; Doder M; Brooks DJ; Lees AJ; et alPiccini P. (1 May 2006). Compulsive drug use linked to sensitized ventral striatal dopamine transmission. ANNALS OF NEUROLOGY. 59:852-858. Author weblink DOI.
  • Brooks DJ; Piccini P. (15 May 2006). Imaging in Parkinson's disease: The role of monoamines in behavior. BIOLOGICAL PSYCHIATRY. 59:908-918. Author weblink DOI.
  • Goerendt IK; Messa C; Lawrence AD; Piccini P; Grasby PM; Brooks DJ. (1 Jun 2001). Endogenous dopamine release during sequential movement in healthy volunteers and patients with Parkinson's disease: a PET study. NEUROIMAGE. 13:S1172-S1172.
  • Piccini P. (1 Dec 2002). Dyskinesias after transplantation in Parkinson's disease. LANCET NEUROLOGY. 1:472-472. Author weblink DOI.
  • Piccini P; Pavese N; Hagell P; Reimer J; Björklund A; Oertel WH; Quinn NP; Brooks DJ; et alLindvall O. (Dec 2005). Factors affecting the clinical outcome after neural transplantation in Parkinson's disease. Brain. 128:2977-2986. DOI.
  • Khan NL; Jain S; Lynch JM; Pavese N; Abou-Sleiman P; Holton JL; Healy DG; Gilks WP; et alSweeney MG; Ganguly M; Gibbons V; Gandhi S; Vaughan J; Eunson LH; Katzenschlager R; Gayton J; Lennox G; Revesz T; Nicholl D; Bhatia KP; Quinn N; Brooks D; Lees AJ; Davis MB; Piccini P; Singleton AB; Wood NW. (1 Dec 2005). Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. BRAIN. 128:2786-2796. Author weblink DOI.
  • Khan NL; Giunti P; Sweeney MG; Scherfler C; Brien MO; Piccini P; Wood NW; Lees AJ. (Sep 2005). Parkinsonism and nigrostriatal dysfunction are associated with spinocerebellar ataxia type 6 (SCA6). Mov Disord. 20:1115-1119. DOI.
  • Ros R; Gómez Garre P; Hirano M; Tai YF; Ampuero I; Vidal L; Rojo A; Fontan A; et alVazquez A; Fanjul S; Hernandez J; Cantarero S; Hoenicka J; Jones A; Ahsan RL; Pavese N; Piccini P; Brooks DJ; Perez-Tur J; Nyggard T; de Yébenes JG. (May 2005). Genetic linkage of autosomal dominant progressive supranuclear palsy to 1q31.1. Ann Neurol. 57:634-641. DOI.
  • Khan NL; Scherfler C; Graham E; Bhatia KP; Quinn N; Lees AJ; Brooks DJ; Wood NW; et alPiccini P. (11 Jan 2005). Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology. 64:134-136. DOI.
  • Piccini P. (Aug 2004). Neurodegenerative movement disorders: the contribution of functional imaging. Curr Opin Neurol. 17:459-466.
  • Scherfler C; Khan NL; Pavese N; Eunson L; Graham E; Lees AJ; Quinn NP; Wood NW; et alBrooks DJ; Piccini PP. (Jun 2004). Striatal and cortical pre- and postsynaptic dopaminergic dysfunction in sporadic parkin-linked parkinsonism. Brain. 127:1332-1342. DOI.
  • Tai YF; Piccini P. (May 2004). Applications of positron emission tomography (PET) in neurology. J Neurol Neurosurg Psychiatry. 75:669-676.
  • Piccini P; Whone A. (May 2004). Functional brain imaging in the differential diagnosis of Parkinson's disease. Lancet Neurol. 3:284-290. DOI.
  • Pavese N; Rimoldi O; Gerhard A; Brooks DJ; Piccini P. (Mar 2004). Cardiovascular effects of methamphetamine in Parkinson's disease patients. Mov Disord. 19:298-303. DOI.
  • Piccini PP. (Oct 2003). Dopamine transporter: basic aspects and neuroimaging. Mov Disord. 18 Suppl 7:S3-S8. DOI.
  • Piccini P; Pavese N; Brooks DJ. (May 2003). Endogenous dopamine release after pharmacological challenges in Parkinson's disease. Ann Neurol. 53:647-653. DOI.
  • Pavese N; Andrews TC; Brooks DJ; Ho AK; Rosser AE; Barker RA; Robbins TW; Sahakian BJ; et alDunnett SB; Piccini P. (May 2003). Progressive striatal and cortical dopamine receptor dysfunction in Huntington's disease: a PET study. Brain. 126:1127-1135.
  • Goerendt IK; Messa C; Lawrence AD; Grasby PM; Piccini P; Brooks DJ; PET study. (Feb 2003). Dopamine release during sequential finger movements in health and Parkinson's disease: a PET study. Brain. 126:312-325.
  • Whone AL; Moore RY; Piccini PP; Brooks DJ. (Feb 2003). Plasticity of the nigropallidal pathway in Parkinson's disease. Ann Neurol. 53:206-213. DOI.
  • Khan NL; Valente EM; Bentivoglio AR; Wood NW; Albanese A; Brooks DJ; Piccini P. (Dec 2002). Clinical and subclinical dopaminergic dysfunction in PARK6-linked parkinsonism: an 18F-dopa PET study. Ann Neurol. 52:849-853. DOI.
  • Khan NL; Brooks DJ; Pavese N; Sweeney MG; Wood NW; Lees AJ; Piccini P. (Oct 2002). Progression of nigrostriatal dysfunction in a parkin kindred: an [18F]dopa PET and clinical study. Brain. 125:2248-2256.
  • Hagell P; Piccini P; Björklund A; Brundin P; Rehncrona S; Widner H; Crabb L; Pavese N; et alOertel WH; Quinn N; Brooks DJ; Lindvall O. (Jul 2002). Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci. 5:627-628. DOI.
  • Kjaer TW; Bertelsen C; Piccini P; Brooks D; Alving J; Lou HC. (Apr 2002). Increased dopamine tone during meditation-induced change of consciousness. Brain Res Cogn Brain Res. 13:255-259.
  • Ceravolo R; Piccini P; Bailey DL; Jorga KM; Bryson H; Brooks DJ. (1 Mar 2002). 18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. Synapse. 43:201-207. DOI.
  • Khan NL; Brooks DJ; Pavese N; Wood NW; Lees AJ; Piccini P. (1 Jan 2002). Progression of nigrostriatal dysfunction in a parkin kindred: An F-18-dopa PET and clinical study. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 72:134-134. Author weblink.
  • Nicholl DJ; Vaughan JR; Khan NL; Ho SL; Aldous DE; Lincoln S; Farrer M; Gayton JD; et alDavis MB; Piccini P; Daniel SE; Lennox GG; Brooks DJ; Williams AC; Wood NW. (Jan 2002). Two large British kindreds with familial Parkinson's disease: a clinico-pathological and genetic study. Brain. 125:44-57.
  • Piccini P; de Yebenez J; Lees AJ; Ceravolo R; Turjanski N; Pramstaller P; Brooks DJ. (Nov 2001). Familial progressive supranuclear palsy: detection of subclinical cases using 18F-dopa and 18fluorodeoxyglucose positron emission tomography. Arch Neurol. 58:1846-1851.
  • Piccini P; Lindvall O; Björklund A; Brundin P; Hagell P; Ceravolo R; Oertel W; Quinn N; et alSamuel M; Rehncrona S; Widner H; Brooks DJ. (Nov 2000). Delayed recovery of movement-related cortical function in Parkinson's disease after striatal dopaminergic grafts. Ann Neurol. 48:689-695.
  • Brundin P; Pogarell O; Hagell P; Piccini P; Widner H; Schrag A; Kupsch A; Crabb L; et alOdin P; Gustavii B; Bjorklund A; Brooks DJ; Marsden CD; Oertel WH; Quinn NP; Rehncrona S; Lindvall O. (1 Jul 2000). Bilateral caudate and putamen grafts of embryonic mesencephalic tissue treated with lazaroids in Parkinson's disease. BRAIN. 123:1380-1390. Author weblink DOI.
  • Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A. (May 2000). The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. J Neurol Neurosurg Psychiatry. 68:589-594.
  • Brooks DJ; Piccini P; Turjanski N; Samuel M. (1 Apr 2000). Neuroimaging of dyskinesia. ANNALS OF NEUROLOGY. 47:S154-S159. Author weblink.
  • Bonuccelli U; Del Dotto P; Lucetti C; Petrozzi L; Bernardini S; Gambaccini G; Rossi G; Piccini P. (1 Jan 2000). Diurnal motor variations to repeated doses of levodopa in Parkinson's disease. CLINICAL NEUROPHARMACOLOGY. 23:28-33. Author weblink DOI.
  • Brooks DJ; Piccini P. (2000). Non-invasive in vivo imaging of transplant function. Prog Brain Res. 127:321-332.
  • Piccini P; Brooks DJ; Björklund A; Gunn RN; Grasby PM; Rimoldi O; Brundin P; Hagell P; et alRehncrona S; Widner H; Lindvall O. (Dec 1999). Dopamine release from nigral transplants visualized in vivo in a Parkinson's patient. Nat Neurosci. 2:1137-1140. DOI.
  • Hagell P; Schrag A; Piccini P; Jahanshahi M; Brown R; Rehncrona S; Widner H; Brundin P; et alRothwell JC; Odin P; Wenning GK; Morrish P; Gustavii B; Bjorklund A; Brooks DJ; Marsden CD; Quinn NP; Lindvall O. (1 Jun 1999). Sequential bilateral transplantation in Parkinson's disease - Effects of the second graft. BRAIN. 122:1121-1132. Author weblink DOI.
  • Ceravolo R; Salvetti S; Piccini P; Lucetti C; Gambaccini G; Bonuccelli U. (May 1999). Acute and chronic effects of clozapine in essential tremor. Mov Disord. 14:468-472.
  • Piccini P; Burn DJ; Ceravolo R; Maraganore D; Brooks DJ. (May 1999). The role of inheritance in sporadic Parkinson's disease: evidence from a longitudinal study of dopaminergic function in twins. Ann Neurol. 45:577-582.
  • Piccini P; Brooks DJ. (1999). Etiology of Parkinson's disease: contributions from 18F-DOPA positron emission tomography. Adv Neurol. 80:227-231.
  • Piccini P; Weeks RA; Brooks DJ. (Nov 1997). Alterations in opioid receptor binding in Parkinson's disease patients with levodopa-induced dyskinesias. Ann Neurol. 42:720-726. DOI.
  • Weeks RA; Cunningham VJ; Piccini P; Waters S; Harding AE; Brooks DJ. (Sep 1997). 11C-diprenorphine binding in Huntington's disease: a comparison of region of interest analysis with statistical parametric mapping. J Cereb Blood Flow Metab. 17:943-949. DOI.
  • Weeks RA; Ceballos-Baumann A; Piccini P; Boecker H; Harding AE; Brooks DJ. (Sep 1997). Cortical control of movement in Huntington's disease. A PET activation study. Brain. 120 ( Pt 9):1569-1578.
  • Piccini P; Morrish PK; Turjanski N; Sawle GV; Burn DJ; Weeks RA; Mark MH; Maraganore DM; et alLees AJ; Brooks DJ. (Feb 1997). Dopaminergic function in familial Parkinson's disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol. 41:222-229. DOI.
  • Weeks RA; Piccini P; Harding AE; Brooks DJ. (Jul 1996). Striatal D1 and D2 dopamine receptor loss in asymptomatic mutation carriers of Huntington's disease. Ann Neurol. 40:49-54. DOI.
  • Lammertsma AA; Turjanski N; Hume SP; Luthra SK; Osman S; Piccini P; Brown DJ; Carroll FI; et alBrooks DJ. (1 May 1996). Quantification of dopamine transporter studies using carbon-11 labelled RTI-121 and PET. JOURNAL OF NUCLEAR MEDICINE. 37:426-426. Author weblink.
  • Piccini P; Pavese N; Paoli C; DelDotto P; Puglioli M; Rossi G; Bonuccelli U. (1 Mar 1996). Are patients with Parkinson's disease more likely to wave periventricular hyperintensities develop? Reply. ARCHIVES OF NEUROLOGY. 53:211-212. Author weblink.
  • PICCINI P; PAVESE N; PALOMBO C; PITTELLA G; DISTANTE A; BONUCCELLI U. (1 Oct 1995). TRANSCRANIAL DOPPLER ULTRASOUND IN MIGRAINE AND TENSION-TYPE HEADACHE AFTER APOMORPHINE ADMINISTRATION - DOUBLE-BLIND CROSSOVER VERSUS PLACEBO STUDY. CEPHALALGIA. 15:399-403. Author weblink DOI.
  • Piccini P; Turjanski N; Brooks DJ. (1 Jan 1995). PET studies of the striatal dopaminergic system in Parkinson's disease (PD). JOURNAL OF NEURAL TRANSMISSION-SUPPLEMENT. 123-131. Author weblink.

Conferences

  • Wu K; O'Keeffe D; Politis M; O'Keeffe G; Bose S; Brooks DJ; Barker R; Piccini P. IN VIVO EVIDENCE OF COMT VAL158MET FUNCTIONAL POLYMORPHISM MODULATES DIFFERENT LEVELS OF DOPAMINE TURNOVER IN PARKINSON'S DISEASE: AN 18F-DOPA PET STUDY. Annual Meeting of the Association-of-British-Neurologists, 2011. 83. B M J PUBLISHING GROUP (1 Mar 2012). DOI.
  • Stokes PR; Clark L; Wu K; Michalczuk R; Watson B; Egerton A; Lappin J; Piccini P; et alNutt D; Bowden-Jones H; Lingford-Hughes A. IMAGING THE DOPAMINE SYSTEM IN PATHOLOGICAL GAMBLING: AN [11C]-RACLOPRIDE PET STUDY. Summer Meeting of the British-Association-for-Psychopharmacology, 24 Jul 2011 - 27 Jul 2011. 25:A61-A61. SAGE PUBLICATIONS LTD (1 Aug 2011). Author weblink.
  • Giannetti P; Politis M; Su P; Turkheimer F; Wu K; Reynolds R; Nicholas R; Piccini P. Two different roles for microglia in vivo in T1 black holes in relapsing and progressive multiple sclerosis?. 21st Meeting of the European-Neurological-Society, 28 May 2011 - 31 May 2011. 258:221-221. SPRINGER HEIDELBERG (1 May 2011). Author weblink.
  • Wu K; O'Sullian S; Politis M; Bose S; Lees A; Piccini P. REWARDING VISUAL CUES INCREASE DOPAMINE NEUROTRANSMISSION IN PARKINSON'S PATIENTS WITH IMPULSE CONTROL DISORDERS: A PET STUDY. Annual Meeting of the Association-of-British-Neurologists, 11 May 2010 - 14 May 2010. 81:E29-E30. B M J PUBLISHING GROUP (1 Nov 2010). DOI.
  • Piccini P. Visualizing new therapeutic concepts in PD - application of PET in cell-based therapy. 12th Congress of the European-Federation-of-Neurological-Societies. 15:393-394. (Aug 2008).
  • Pavese N; Khan NL; Wood NW; Quinn NP; Lees AJ; Brooks DJ; Piccini P. Nigrostriatal dysfunction in parkin linked parkinsonism and asymptomatic heterozygous carriers: A progressive study with 18-dopa pet. Annual Meeting of the Association-of-British-Neurologists, 14 Nov 2007 - 16 Nov 2007. 79:341-341. B M J PUBLISHING GROUP (1 Mar 2008). Author weblink.
  • Pavese N; Gerhard A; Tai YF; Ho AK; Turkheimer F; Barker RA; Brooks DJ; Piccini P. In vivo imaging of activated microglia by 11C-(R)-PK11195 PET. A biomarker of neuroinflammation in Huntington's disease?. World Congress on Huntingtons Disease. 76:U26-U27. (Oct 2005).
  • Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P. Microglial activation in presymptomatic Huntington's disease gene carriers: A C-11-PK11195 pet study. World Congress on Huntingtons Disease. 76:U5-U5. (Oct 2005).
  • Tai YF; Pavese N; Gerhard A; Tabrizi SJ; Barker RA; Brooks DJ; Piccini P. Imaging activated microglia in presymptomatic Huntington's disease gene carriers: An 11C-PK11195 PET study. Clinical Neurosciences 2005 Meeting. 77:138-138. (Jan 2006).
  • Khan NL; Bhatt M; Brooks DJ; Korlipara P; Schapira A; Piccini P; Wood NW; Bhatia K. An Indian kindred with reversible dystonia and parkinsonism. Fall Meeting of the Association-of-British-Neurologists. 78:210-210. (Feb 2007).
Share this on Delicious
Tweet this
Digg this
Stumble this
Share this on Facebook